Innovation Pharmaceuticals Cites Recent Academic Literature Showing Host Defense Proteins at Cutting-Edge of Medicine for Multiple Diseases

BEVERLY, Mass., October 8, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of published Host Defense Protein/Peptide (HDP) basic research insights that reinforce the therapeutic potential of Brilacidin, the Company’s novel HDP-mimetic drug candidate.

Brilacidin has been successfully evaluated in mid-stage clinical studies in three different indications: Acute Bacterial Skin and Skin Structure Infection (Phase 2b, intravenously administered); Oral Mucositis (Phase 2, oral rinse); and Ulcerative Proctitis/Ulcerative Proctosigmoiditis (Phase 2 Proof-of-Concept, retention enema). Extension of Brilacidin as a topical agent into dermatological diseases, such as Atopic Dermatitis, also is planned. In July 2019, Brilacidin was licensed to Italy’s Alfasigma S.p.A for local treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. During development and with successful commercialization, milestone-based payments totaling $24 million, plus royalties, would be paid to Innovation.

Of note in the academic literature is an emphasis on various mechanistic functions and roles that make HDP-based drug candidates, like Brilacidin, so promising. One article concludes:

The multi-faceted nature of HDPs and their ability to influence a wide range of biological processes opens the door to expanding our understanding of other activity landscapes within the chemical space of HDPs. As our understanding of these other activity types improves, and the mechanistic details underpinning these other processes are laid bare, this will undoubtedly lead to the development of HDP based drugs that are effective against infectious diseases as well as inflammatory conditions.

“It’s extremely rewarding to see extensive academic research on HDP mechanisms continue to be published that supports Brilacidin’s broad therapeutic potential,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “As many Pharmas are starting to realize based on our partnering interactions, HDPs represent a potentially transformative drug class, with Brilacidin clearly the leading example. Should Brilacidin gain regulatory approval, hundreds of thousands of patients may one day benefit from its use.”

To the point that the Company’s HDP franchise has the potential to treat a broad spectrum of diseases and conditions, further information can be found in a blog posted on the Company’s website providing some color to the opportunity, as supported by recent literature:

·       “Literature Supporting Therapeutic Potential of Host Defense Peptide/Protein (HDP)-Based Drug Candidates Such as Brilacidin”

http://www.ipharminc.com/new-blog/2019/10/8/literature-supporting-therapeutic-potential-of-host-defense-peptide-protein-hdp-based-drug-candidates-such-as-brilacidin